Ignite Creation Date:
2024-05-06 @ 7:51 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06161259
Status:
COMPLETED
Last Update Posted:
2023-12-07
First Post:
2023-11-30
Brief Title:
Pharmacokinetics of LeritrelvirRAY1216 in Participants With Hepatic Impairment
Sponsor:
Guangdong Raynovent Biotech Co Ltd
Organization:
Guangdong Raynovent Biotech Co Ltd
Study Overview
Official Title:
A Phase I Single Dose Non-Randomised Open-Label Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics Safety and Tolerability of LeritrelvirRAY1216
Status:
COMPLETED
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will assess the effect of hepatic impairment on the pharmacokinetics PK safety and tolerability of LeritrelvirRAY1216
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None